Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin
Qiou Wei1, Hong Jiang, Connie P Matthews
1Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Abstract:
Previous studies have shown that a dominant negative form of c-Jun (TAM67) suppresses mouse skin carcinogenesis both in vitro and in vivo. The current study identifies Sulfiredoxin (Srx) as a unique target of activator protein-1 (AP-1) activation and TAM67 inhibition. Manipulation of Srx levels by ShRNA or over-expression demonstrates that Srx is critical for redox homeostasis through reducing hyperoxidized peroxiredoxins. In JB6 cells, knockdown of Srx abolishes tumor promoter-induced transformation and enhances cell sensitivity to oxidative stress. Knockdown of Srx also impairs c-Jun phosphorylation, implicating a role for Srx in the feedback regulation of AP-1 activity. Screening of patient tissues by tissue microarray reveals elevated Srx expression in several types of human skin cancers. Our study indicates that Srx is a functionally significant target of AP-1 blockade that may have value in cancer prevention or treatment.
Insights
Sulfiredoxin (Srx) is a novel target of activator protein-1 (AP-1) that plays a critical role in skin cancer. Inhibiting Srx may offer a new strategy for cancer prevention and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Dominant-negative c-Jun (TAM67) inhibits skin carcinogenesis.
- Activator protein-1 (AP-1) is a key transcription factor in carcinogenesis.
Purpose of the Study:
- Identify novel targets of AP-1 activation and TAM67 inhibition.
- Investigate the role of Sulfiredoxin (Srx) in skin carcinogenesis and redox homeostasis.
Main Methods:
- Utilized short hairpin RNA (shRNA) and overexpression to manipulate Srx levels.
- Assessed Srx function in JB6 cells regarding transformation and oxidative stress sensitivity.
- Examined c-Jun phosphorylation and AP-1 activity.
- Screened patient skin cancer tissues using tissue microarrays.
Main Results:
- Identified Sulfiredoxin (Srx) as a unique target of AP-1 and TAM67.
- Demonstrated Srx's critical role in maintaining redox homeostasis by reducing hyperoxidized peroxiredoxins.
- Showed that Srx knockdown abolishes tumor promoter-induced transformation and increases oxidative stress sensitivity in JB6 cells.
- Found that Srx knockdown impairs c-Jun phosphorylation, suggesting a feedback role in AP-1 regulation.
- Observed elevated Srx expression in human skin cancers.
Conclusions:
- Srx is a significant target of AP-1 blockade.
- Srx plays a crucial role in redox balance and cellular transformation.
- Targeting Srx presents a potential therapeutic strategy for skin cancer prevention and treatment.
Related Concept Videos
Sulfur Assimilation
Abnormal Proliferation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
TGF - β Signaling Pathway
Gene Regulation in Microbial Communities: Quorum Sensing

